Hematology NewsASCT may cure follicular lymphoma for some rituximab-naive patientsSeptember 24, 2019Follicular LymphomaB Cell LymphomaTransplantationTransplantLymphoma & Plasma Cell Disorders
Hematology NewsObinutuzumab-lenalidomide combo shows promise in relapsed/refractory FLAugust 21, 2019Follicular LymphomaLymphoma & Plasma Cell DisordersB Cell Lymphoma
Hematology NewsFDA approves rituximab biosimilar for cancer, autoimmune disordersJuly 23, 2019B Cell LymphomaCLLLymphoma & Plasma Cell DisordersFollicular Lymphoma
Hematology NewsCAR T-cell therapy less effective in transformed follicular lymphomaJuly 22, 2019Follicular LymphomaLymphoma & Plasma Cell DisordersB Cell LymphomaCellular TherapyDLBCL
Hematology News5F9 plus rituximab take a bite out of drug-resistant NHLJune 18, 2019Aggressive LymphomasIndolent LymphomaLymphoma & Plasma Cell DisordersB Cell LymphomaFollicular Lymphoma
Hematology NewsR2 appears active in high-risk FL and MZLJune 14, 2019B Cell LymphomaLymphoma & Plasma Cell DisordersIndolent LymphomaFollicular LymphomaRare Diseases
Hematology NewsInhibitor produces high response rate in relapsed/refractory FLJune 11, 2019Follicular LymphomaB Cell LymphomaLymphoma & Plasma Cell Disorders
Hematology NewsFDA approves lenalidomide/rituximab for previously treated FL, MZLMay 29, 2019B Cell LymphomaLymphoma & Plasma Cell DisordersIndolent LymphomaFollicular Lymphoma
Hematology NewsTrial follow-up spotlights survival gains in follicular lymphomaMay 16, 2019Follicular LymphomaB Cell LymphomaLymphoma & Plasma Cell Disorders
Hematology TimesIn situ vaccination produced responses in indolent NHLApril 8, 2019B Cell LymphomaIndolent LymphomaLymphoma & Plasma Cell DisordersFollicular Lymphoma
Hematology NewsPolatuzumab outperforms pinatuzumab in non-Hodgkin lymphomaApril 5, 2019B Cell LymphomaLymphoma & Plasma Cell DisordersFollicular Lymphoma
Hematology NewsHigh survival in relapsed FL after primary radiotherapyMarch 21, 2019Follicular LymphomaLymphoma & Plasma Cell DisordersIndolent LymphomaB Cell Lymphoma
Hematology NewsAnthracyclines, bendamustine are options for grade 3A follicular lymphomaFebruary 11, 2019Follicular LymphomaAggressive LymphomasLymphoma & Plasma Cell DisordersB Cell Lymphoma
Hematology NewsDaratumumab disappoints in non-Hodgkin lymphoma trialFebruary 11, 2019Mantle Cell LymphomaLymphoma & Plasma Cell DisordersFollicular LymphomaB Cell Lymphoma
Hematology NewsBCL expression intensity key in distinguishing FL lesionsFebruary 10, 2019Indolent LymphomaLymphoma & Plasma Cell DisordersFollicular LymphomaNonmelanoma Skin CancerB Cell Lymphoma
